0O9B Stock Chart & Stats
€12.90
-€0.04(-0.52%)
At close: 4:00 PM EST
€12.90
-€0.04(-0.52%)
Day’s Range― - ―
52-Week Range€10.12 - €13.98
Previous CloseN/A
Volume457.00
Average Volume (3M)2.60K
Market Cap
€2.46B
Enterprise Value€2.44B
Total Cash (Recent Filing)€311.20M
Total Debt (Recent Filing)€285.40M
Price to Earnings (P/E)46.4
Beta1.02
Next Earnings
Jul 24, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding217,777,330
10 Day Avg. Volume4,186
30 Day Avg. Volume2,602
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)1.85
Price to Sales (P/S)2.49
P/FCF Ratio20.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.38
Revenue Forecast (FY)€1.23B
Bulls Say, Bears Say
Bulls Say
Revenue & Margin RecoverySustained acceleration in revenue alongside meaningful EBITDA margin expansion indicates that core dermatology products are scaling profitably. This structural improvement supports reinvestment in R&D and commercial expansion, improving long-term cash generation and operational resilience.
Conservative Balance SheetLower leverage and a stable equity base reduce refinancing and liquidity risk, giving management flexibility to fund late-stage development, commercial launches, or targeted M&A. Conservatism in capital structure supports durability across industry cycles and pricing pressure.
Durable Clinical Data For LebrikizumabFour-year sustained efficacy and a consistent safety profile materially strengthen the long-term commercial case for lebrikizumab in atopic dermatitis. Durable clinical outcomes improve prescribing confidence, extend product lifecycle value, and reduce regulatory/launch execution risk.
Bears Say
Thin Net ProfitabilityA low net margin limits internal cash available for growth and makes earnings more sensitive to input cost rises or pricing/reimbursement pressure. Over the medium term, persistently thin profitability can hinder funding for R&D and commercial scale relative to peers.
Cash-flow VolatilityMaterial swings from negative to positive free cash flow suggest working-capital or investment timing effects; uneven FCF amplifies execution risk for launches and makes sustainable dividend or buyback policies harder to maintain across cycles.
Low Returns On CapitalROE near 4% signals the business is not yet converting profits into strong shareholder returns. Persistently low returns constrain ability to self-fund growth and reduce buffer against competitive or pricing shocks in specialty dermatology markets.
Almirall News
0O9B FAQ
What was Almirall SA’s price range in the past 12 months?
Almirall SA lowest share price was €10.12 and its highest was €13.98 in the past 12 months.
What is Almirall SA’s market cap?
Almirall SA’s market cap is €2.46B.
When is Almirall SA’s upcoming earnings report date?
Almirall SA’s upcoming earnings report date is Jul 24, 2026 which is in 24 days.
How were Almirall SA’s earnings last quarter?
Almirall SA released its earnings results on May 11, 2026. The company reported €0.071 earnings per share for the quarter, missing the consensus estimate of €0.09 by -€0.019.
Is Almirall SA overvalued?
According to Wall Street analysts Almirall SA’s price is currently Overvalued.
Does Almirall SA pay dividends?
Almirall SA does not currently pay dividends.
What is Almirall SA’s EPS estimate?
Almirall SA’s EPS estimate is 0.09.
How many shares outstanding does Almirall SA have?
Almirall SA has 217,777,330 shares outstanding.
What happened to Almirall SA’s price movement after its last earnings report?
Almirall SA reported an EPS of €0.071 in its last earnings report, missing expectations of €0.09. Following the earnings report the stock price went down -2.483%.
Which hedge fund is a major shareholder of Almirall SA?
Currently, no hedge funds are holding shares in GB:0O9B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Almirall Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.06%
12-Months-Change
Fundamentals
Return on Equity
3.53%
Trailing 12-Months
Asset Growth
-2.48%
Trailing 12-Months
Company Description
Almirall SA
Almirall, S.A. is a biopharmaceutical firm dedicated to the discovery, development, production, and commercialization of treatments primarily focused on skin health. Operating globally, with a significant presence in Europe and the United States, its product line targets various dermatological ailments such as actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, and acne, alongside rare skin conditions. Beyond its core dermatology focus, the company also offers solutions for cardiovascular, musculoskeletal, respiratory, and nervous system disorders, as well as products for digestive health, anti-infectives for systemic use, genitourinary conditions and sex hormones, immunostimulants, and systemic hormonal preparations. Its extensive portfolio includes a range of well-known medications, such as Ilumetri, Solaraze, Skilarence, and Klisyri, among others. Almirall fosters strategic partnerships with numerous entities to advance its pipeline, including research institutions like the University of Dundee and commercial partners such as Eli Lilly and Company. Founded in Barcelona, Spain, in 1943, the company adopted its current name, Almirall, S.A., in May 2009, having previously been known as Laboratorios Almirall, S.A.
Technical Analysis
Options Prices
Currently, No data available
---